Compare Novavax Inc (NVAX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs J M Smucker Co — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while J M Smucker Co trades at $117.46 (market cap $12.54B). The key difference: J M Smucker Co is far larger — about 9.6× Novavax Inc's market cap, and J M Smucker Co pays a 3.82% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SJM | |
|---|---|---|
Market Cap | $1.31B | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $126.35 |
52-Week Low | $6.22 | $89.53 |
Enterprise Value | $889.30M | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
SJM trades at $118.84, up 0.65% today, with a bullish technical signal and support near $117. The company reported revenue of $8.73B in 2025 but a net loss of -$1.23B, though recent quarters show earnings beats. Analyst consensus is a Buy with a $125.11 price target, and the dividend was recently increased to $1.12 per share, marking 25 consecutive years of growth.
Outlook is mixed: strong cash flow and dividend growth support income investors, but negative margins and high debt pose risks. Upside depends on cost controls and Uncrustables growth offsetting sales declines. The stock offers value at a P/E of 22.05 but faces execution challenges in a competitive consumer staples market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
